A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs APG-5918 (Primary)
Indications B-cell lymphoma; Carcinoma; Gastric cancer; Mesothelioma; Nasopharyngeal cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Prostate cancer; Sarcoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Ascentage Pharma

11 Nov 2022 Status changed from not yet recruiting to recruiting.
29 Jun 2022 According to an Ascentage Pharma media release, APG-5918, has been cleared by the US Food and Drug Administration (FDA) to enter a first-in-human (FIH) study that will assess the safety, pharmacokinetics, and preliminary efficacy of APG-5918 in patients with solid tumors or hematologic malignancies.
27 Jun 2022 Planned number of patients changed from 84 to 90.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com